3/4
04:58 pm
cstl
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB [Yahoo! Finance]
Low
Report
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB [Yahoo! Finance]
3/4
04:30 pm
cstl
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
Low
Report
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB
3/4
05:51 am
cstl
Castle Biosciences (CSTL) was downgraded by Zacks Research from "strong-buy" to "hold".
Low
Report
Castle Biosciences (CSTL) was downgraded by Zacks Research from "strong-buy" to "hold".
3/3
05:00 pm
cstl
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas [Yahoo! Finance]
Low
Report
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas [Yahoo! Finance]
3/3
04:30 pm
cstl
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
Low
Report
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
3/2
07:01 am
cstl
Castle Biosciences (CSTL) was upgraded by Morgan Stanley to "buy".
Medium
Report
Castle Biosciences (CSTL) was upgraded by Morgan Stanley to "buy".
2/27
08:02 am
cstl
Castle Biosciences (CSTL) had its price target raised by Robert W. Baird from $41.00 to $44.00. They now have an "outperform" rating on the stock.
Medium
Report
Castle Biosciences (CSTL) had its price target raised by Robert W. Baird from $41.00 to $44.00. They now have an "outperform" rating on the stock.
2/26
05:59 pm
cstl
Castle Biosciences Q4 Earnings Call Highlights [Yahoo! Finance]
High
Report
Castle Biosciences Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
04:32 pm
cstl
Castle Biosciences Non-GAAP EPS of -$0.08 beats by $0.18, revenue of $87M beats by $6.69M [Seeking Alpha]
High
Report
Castle Biosciences Non-GAAP EPS of -$0.08 beats by $0.18, revenue of $87M beats by $6.69M [Seeking Alpha]
2/26
04:05 pm
cstl
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
Medium
Report
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
2/19
05:46 pm
cstl
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
Medium
Report
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
2/5
06:43 pm
cstl
What Catalysts Are Rewriting The Castle Biosciences (CSTL) Story For Wall Street Analysts [Yahoo! Finance]
Low
Report
What Catalysts Are Rewriting The Castle Biosciences (CSTL) Story For Wall Street Analysts [Yahoo! Finance]
2/5
07:18 am
cstl
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 [Yahoo! Finance]
Medium
Report
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 [Yahoo! Finance]
2/5
07:00 am
cstl
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
Medium
Report
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026
2/4
06:43 am
cstl
Castle Biosciences (NASDAQ:CSTL) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Castle Biosciences (NASDAQ:CSTL) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/29
04:06 pm
cstl
Castle Biosciences (NASDAQ:CSTL) had its "overweight" rating reaffirmed by analysts at KeyCorp.
Low
Report
Castle Biosciences (NASDAQ:CSTL) had its "overweight" rating reaffirmed by analysts at KeyCorp.
1/26
10:59 am
cstl
Castle Biosciences (NASDAQ:CSTL) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Castle Biosciences (NASDAQ:CSTL) had its "buy" rating reaffirmed by analysts at Guggenheim.
1/12
10:04 am
cstl
Castle Biosciences (NASDAQ:CSTL) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
Low
Report
Castle Biosciences (NASDAQ:CSTL) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
1/12
02:40 am
cstl
The Bull Case For Castle Biosciences (CSTL) Could Change Following Surging Test Volumes And Raised 2025 Outlook [Yahoo! Finance]
Low
Report
The Bull Case For Castle Biosciences (CSTL) Could Change Following Surging Test Volumes And Raised 2025 Outlook [Yahoo! Finance]
1/12
01:41 am
cstl
Castle Biosciences (CSTL) Valuation After Upgraded 2025 Guidance And Strong Core Test Volume Growth [Yahoo! Finance]
Low
Report
Castle Biosciences (CSTL) Valuation After Upgraded 2025 Guidance And Strong Core Test Volume Growth [Yahoo! Finance]
1/11
07:40 pm
cstl
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results [Yahoo! Finance]
Low
Report
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results [Yahoo! Finance]
1/11
04:00 pm
cstl
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
Low
Report
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
1/6
07:25 am
cstl
Castle Biosciences (NASDAQ:CSTL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Castle Biosciences (NASDAQ:CSTL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
1/5
10:16 am
cstl
Castle Biosciences (NASDAQ:CSTL) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Castle Biosciences (NASDAQ:CSTL) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/22
08:02 am
cstl
Castle Biosciences (NASDAQ:CSTL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $37.00 to $50.00. They now have a "buy" rating on the stock.
Medium
Report
Castle Biosciences (NASDAQ:CSTL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $37.00 to $50.00. They now have a "buy" rating on the stock.